Introduction

Families often wonder which joint treatments are suitable for older relatives. The ChondroFiller injection is one non-surgical option that may help support a worn joint. This article looks at how suitability is judged, with realistic expectations throughout.

ChondroFiller and Age

ChondroFiller is a CE-marked, acellular type I collagen scaffold that is delivered as a non-surgical, ultrasound-guided injection directly into the joint. Once in place, it self-gels and forms a porous three-dimensional matrix over the worn surface. This may help cushion the joint and reduce discomfort. The scaffold works by recruiting the patient's own progenitor cells, which gradually remodel the matrix towards cartilage-like tissue. Age alone is not the deciding factor for suitability.

Assessing Suitability

Clinicians look beyond age when assessing whether the ChondroFiller injection is appropriate. The degree of joint wear matters: the treatment is generally suited to ICRS Grade I–IV focal cartilage defects in joints that remain reasonably well-aligned and structurally stable. Very advanced, diffuse arthritis may be better managed by other means. A patient's general health, activity level, and any underlying conditions that might affect healing are also considered. An older person with mild to moderate joint wear and reasonable general health may be a reasonable candidate, while someone with severe joint deformity or significant comorbidities would need careful assessment before proceeding.

The ChondroFiller Injection and Surgical Alternatives

People sometimes ask how the ChondroFiller injection compares with options that involve cells or surgery. It is helpful to understand that there are two distinct pathways at LCC.

The ChondroFiller injection is delivered in an outpatient or clinic setting under ultrasound guidance, with no theatre, no general anaesthetic, and no incision. It introduces no cells of its own; the scaffold is acellular and relies on the patient's endogenous progenitor cells to populate it over time. This makes it a relatively straightforward non-surgical intervention suited to accessible lesions and smaller or less complex defects.

Where a defect is larger, in a high-load-bearing location, or where biologics and mesenchymal stem cells (MSCs) are judged to be beneficial, the appropriate route is the Liquid Cartilage procedure — Professor Paul Y. F. Lee's keyhole (arthroscopic) surgical protocol. Liquid Cartilage is not the same thing as the ChondroFiller injection. It is a distinct surgical technique that places the ChondroFiller scaffold arthroscopically, combining it with biological adjuncts such as platelet-rich fibrin, platelet-rich plasma, and, where indicated, the patient's own MSCs from bone-marrow aspirate concentrate or micro-fragmented fat. This is genuine keyhole surgery requiring theatre, anaesthetic, and a structured rehabilitation programme. For older adults, the clinician will weigh fitness for surgery and overall health when advising on whether the injection pathway or the surgical Liquid Cartilage pathway is the more appropriate choice.

The Role of Expert Assessment

Advanced joint care benefits from specialist expertise. A thorough assessment — including examination, imaging, and a review of general health — helps determine whether the ChondroFiller injection is suitable, whether the Liquid Cartilage surgical protocol would be more appropriate, or whether a different management strategy altogether should be considered. At the London Cartilage Clinic, individual assessment is provided with realistic guidance for each patient's circumstances.

Realistic Expectations

Outcomes from the ChondroFiller injection vary: some patients experience meaningful improvement in symptoms, others less so, and benefits cannot be guaranteed. Published clinical experience with ChondroFiller indicates significant improvement in patient-reported outcome scores over 12 to 36 months across a range of joints, but individual results depend on joint condition, defect characteristics, and adherence to post-procedure guidance. The injection is not a cure for arthritis and does not reverse established joint degeneration.

Conclusion

Age plays a role in planning joint care, but it is not the deciding factor for ChondroFiller injection suitability — joint condition, defect characteristics, and overall health matter most. For some older adults this non-surgical injection may offer meaningful support. For those where a surgical approach is indicated, the Liquid Cartilage keyhole procedure provides a distinct and more comprehensive pathway. For individual advice, a consultation with a qualified joint preservation specialist is the appropriate first step.

References

Corain M, Zanotti F, Giardini M, Gasperotti L, Invernizzi E, Biasi V, Lavagnolo U. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage. 2023.